It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish.
ABBV (@Pharmaceuticals: Major) experienced а +2.00% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.91%. For the same industry, the average monthly price growth was +5.75%, and the average quarterly price growth was +4.68%.
ABBV is expected to report earnings on Jul 25, 2025.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
ABBV | ||
---|---|---|
OUTLOOK RATING 1..100 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 11 | |
SMR RATING 1..100 | 14 | |
PRICE GROWTH RATING 1..100 | 54 | |
P/E GROWTH RATING 1..100 | 14 | |
SEASONALITY SCORE 1..100 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV | AVK | |
---|---|---|
RSI ODDS (%) | N/A | 1 day ago81% |
Stochastic ODDS (%) | 1 day ago44% | 1 day ago82% |
Momentum ODDS (%) | 1 day ago66% | 1 day ago77% |
MACD ODDS (%) | 1 day ago66% | 1 day ago78% |
TrendWeek ODDS (%) | 1 day ago57% | 1 day ago87% |
TrendMonth ODDS (%) | 1 day ago59% | 1 day ago88% |
Advances ODDS (%) | 1 day ago56% | 1 day ago86% |
Declines ODDS (%) | 17 days ago46% | 16 days ago84% |
BollingerBands ODDS (%) | 1 day ago62% | 1 day ago78% |
Aroon ODDS (%) | N/A | 1 day ago87% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
BBHLX | 19.62 | 0.02 | +0.10% |
BBH Partner Fund - International Eq I | |||
GITCX | 14.95 | N/A | N/A |
Goldman Sachs Technology Opps C | |||
TQVAX | 17.50 | N/A | N/A |
T. Rowe Price Integrated US LCV Eq Adv | |||
HDGRX | 34.61 | N/A | N/A |
Hartford Dividend and Growth R3 | |||
MVGJX | 17.83 | N/A | N/A |
MFS Low Volatility Global Equity R1 |
A.I.dvisor tells us that AVK and ABBV have been poorly correlated (+3% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVK and ABBV's prices will move in lockstep.
Ticker / NAME | Correlation To AVK | 1D Price Change % | ||
---|---|---|---|---|
AVK | 100% | +0.43% | ||
ABBV - AVK | 3% Poorly correlated | +1.26% |